ANKTIVA is a first-of-its-kind engineered immune-boosting protein placed into the bladder alongside standard bacterial therapy for early bladder cancer that has stopped responding. Many people clear their cancer and keep their bladder for two years or more. Benefit is strongest for the flat, lining-confined form. Side effects are mostly local and mild; evidence comes from one uncontrolled maker-funded study. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Serum creatinine | 0.7–1.1 mg/dL | Detects the common treatment-associated rise in kidney marker |
| Serum potassium | 4.0–4.5 mmol/L | Catches the reported increases in potassium |
| Urine cytology | Negative for malignant cells | Non-invasive check for persistent or recurrent cancer |
| Cystoscopic findings | No visible tumor | Direct visualization is the primary success measure |
Cadence: Reassessment by cystoscopy and cytology at about month 3, then at regular surveillance intervals (commonly every 3 months in the first years, lengthening thereafter); kidney and electrolyte labs checked periodically.